The Biological Therapy of Cancer

The current status of biological approaches to the therapy of malignancy is reviewed. Biological response modifiers have been used in immunobiological therapeutic strategies, as myelorestorative agents during chemotherapy, as modulators of cytotoxic chemotherapeutic actions, and as adjuncts to the d...

Full description

Saved in:
Bibliographic Details
Main Author: David R Parkinson
Format: Article
Language:English
Published: Wiley 1992-01-01
Series:Canadian Journal of Infectious Diseases
Online Access:http://dx.doi.org/10.1155/1992/420495
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850222943800393728
author David R Parkinson
author_facet David R Parkinson
author_sort David R Parkinson
collection DOAJ
description The current status of biological approaches to the therapy of malignancy is reviewed. Biological response modifiers have been used in immunobiological therapeutic strategies, as myelorestorative agents during chemotherapy, as modulators of cytotoxic chemotherapeutic actions, and as adjuncts to the differentiation therapy of cancer. Immunobiologically active agents currently under study include recombinant cytokines such as interferons-alpha and -gamma. interleukin (IL)-1 and IL-2. and tumuor necrosis factor. A range of hematopoietic growth factors are being studied alone or in combination; these include granulocyte-. granulocyte-macrophage- and macrophage-colony stimulating factors, IL-3 and IL-6. and the recombinant growth factor PIXY-321. Targetting strategies to cytotoxic cancer therapy including immunoloxin and radioimmunoconjugate therapy have used monocolonal antibodies and derivative bio-engineered molecules as targetting modalities. Finally. the recent descriptions of therapeutic successes with retinoid-based differentiation strategies opens new possibilities for biologically-based treatment of malignancy.
format Article
id doaj-art-6c3140a62bab46bca868703d96dc6c7d
institution OA Journals
issn 1180-2332
language English
publishDate 1992-01-01
publisher Wiley
record_format Article
series Canadian Journal of Infectious Diseases
spelling doaj-art-6c3140a62bab46bca868703d96dc6c7d2025-08-20T02:06:07ZengWileyCanadian Journal of Infectious Diseases1180-23321992-01-013Suppl B263310.1155/1992/420495The Biological Therapy of CancerDavid R ParkinsonThe current status of biological approaches to the therapy of malignancy is reviewed. Biological response modifiers have been used in immunobiological therapeutic strategies, as myelorestorative agents during chemotherapy, as modulators of cytotoxic chemotherapeutic actions, and as adjuncts to the differentiation therapy of cancer. Immunobiologically active agents currently under study include recombinant cytokines such as interferons-alpha and -gamma. interleukin (IL)-1 and IL-2. and tumuor necrosis factor. A range of hematopoietic growth factors are being studied alone or in combination; these include granulocyte-. granulocyte-macrophage- and macrophage-colony stimulating factors, IL-3 and IL-6. and the recombinant growth factor PIXY-321. Targetting strategies to cytotoxic cancer therapy including immunoloxin and radioimmunoconjugate therapy have used monocolonal antibodies and derivative bio-engineered molecules as targetting modalities. Finally. the recent descriptions of therapeutic successes with retinoid-based differentiation strategies opens new possibilities for biologically-based treatment of malignancy.http://dx.doi.org/10.1155/1992/420495
spellingShingle David R Parkinson
The Biological Therapy of Cancer
Canadian Journal of Infectious Diseases
title The Biological Therapy of Cancer
title_full The Biological Therapy of Cancer
title_fullStr The Biological Therapy of Cancer
title_full_unstemmed The Biological Therapy of Cancer
title_short The Biological Therapy of Cancer
title_sort biological therapy of cancer
url http://dx.doi.org/10.1155/1992/420495
work_keys_str_mv AT davidrparkinson thebiologicaltherapyofcancer
AT davidrparkinson biologicaltherapyofcancer